NFKB1 and cancer: CGs have anti-tumorigenesis through affects in multiple pathways, which include reducing the cellular membrane potential, an intracellular concentration of K+, increasing the intracellular Na+ and Ca++ to induce apoptosis, like topoisomerase inhibitor, suppressing NF-κB activity, interacting with phospholipid to interfere receptor binding, and modifying N-glycosylation to inhibit cancer cell migration and invasion [39].